

1 **Supplemental Information**

2

3 **NF- $\kappa$ B drives epithelial-mesenchymal mechanisms of lung**  
4 **fibrosis in a translational lung cell model**

5 Patrick Sieber<sup>1\*</sup>, Anny Schäfer<sup>1</sup>, Raphael Lieberherr<sup>1</sup>, Silvia L. Caimi<sup>1</sup>, Urs Lüthi<sup>1</sup>, Jesper  
6 Ryge<sup>1</sup>, Jan H. Bergmann<sup>1</sup>, François Le Goff<sup>1</sup>, Manuel Stritt<sup>1</sup>, Peter Blattmann<sup>1</sup>, Bérengère  
7 Renault<sup>1</sup>, Patrick Rammelt<sup>1</sup>, Bruno Sempere<sup>1</sup>, Diego Freti<sup>1</sup>, Rolf Studer<sup>1</sup>, Eric S. White<sup>2, †</sup>,  
8 Magdalena Birker–Robaczewska<sup>1</sup>, Maxime Boucher<sup>1</sup>, and Oliver Nayler<sup>1</sup>

9

10

## 11 **Methods**

### 12 *Cells*

13 Normal human lung fibroblasts (FB) (NHLF; Lonza, CC–2512) and IPF patient–derived FB  
14 (IHLF; Asterand, 16769) were used between passage 4 and 8 and cultivated in FB growth  
15 medium 2 (FGM–2; Lonza), supplemented with 100 units/ml of penicillin and 100 µg/ml of  
16 streptomycin, following the supplier's instructions. Normal human bronchial epithelial cells  
17 (EC) (i.e. NHBE; Lonza, CC–2541), NHBEC (Lonza, CC–2540) or HBEpiC (ScienCell, 3210–  
18 1ea), as well as human tracheal EC (HTEC; Cell Applications, 06090742) were used between  
19 passage 3 and 4 and cultivated in bronchial epithelial cell growth medium (BEGM; Lonza)  
20 supplemented according to the supplier's instructions. The NHBE and HBEpiC were used  
21 interchangeably in co–culture with comparable effects and are abbreviated as NHBE in the  
22 text for simplicity. The human lung epithelial cell lines NCI–H2452 (ATCC, CRL–5946), A549  
23 (ATCC, CCL–185), NCI–H1975 (ATCC, CRL–5908) and NCI–H1650 (ATCC, CRL–5883)  
24 were cultured in RPMI 1640 (Gibco) supplemented with 10% (vol/vol) heat–inactivated FBS  
25 (Gibco) and 100 units/ml of penicillin and 100 µg/ml of streptomycin. Human lung epithelial  
26 cell lines Calu3 (ATCC, HTB–55) and A427 (ATCC, HTB–53) were cultivated in MEM Eagle  
27 medium (Gibco) supplemented with 10% (vol/vol) heat–inactivated FBS (Gibco), 2 mM L–  
28 Glutamine, 0.1 mM non–essential amino acids (NEAA), 1 mM Sodium Pyruvate and 100  
29 units/ml of penicillin and 100 µg/ml of streptomycin. Human umbilical vein endothelial cells  
30 (HUVEC; Cascade Biologics,) were used at passage 8 and grown in Medium 200 (Cascade  
31 Biologics) supplemented with low serum growth supplement (Gibco, S–003–10) and 100  
32 units/ml of penicillin and 100 µg/ml of streptomycin following the supplier's instructions. Normal  
33 human bronchial smooth muscle cells (BSMC; Lonza, CC–2576) and human pulmonary artery  
34 smooth muscle cells (PASMC; Cell Applications, 352–05a) were used between passage 4 and

35 8 and cultivated in smooth muscle growth medium 2 (SmGM-2; Lonza), supplemented with  
36 100 units/ml of penicillin and 100 µg/ml of streptomycin, following the supplier's instructions.

### 37 *Phenotypic HCA*

38 For the high-content assay (HCA), NHLF and NHBE were seeded into standard cell culture  
39 vessels 5 days prior to the experiment using their appropriate complete media. Each well of a  
40 384-well clear bottom microtiter plate (Cell Carrier Ultra; Perkin Elmer) was coated with 0.1%  
41 laminin solution for 60 min at 37 °C and rinsed once with 1 x phosphate buffered saline (PBS,  
42 Gibco). NHBE were stained with CellTracker™ Deep Red (Thermo Fisher Scientific) diluted in  
43 1 x PBS according to the manufacture's protocol. NHLF cells were seeded at a density of 2000  
44 cells/well in a volume of 20 µl FB basal medium (FBM, Lonza) supplemented with 0.1% fatty  
45 acid-free BSA, 100 units/ml of penicillin and 100 µg/ml of streptomycin and 250 ng/ml  
46 amphotericin B in combination with 800 cells/well NHBE in 20 µl starvation medium (FBM;  
47 Lonza) and grown for 48h at 37 °C, 5 % CO<sub>2</sub> and 95 % relative humidity. Control NHLF were  
48 grown in complete FB growth medium (FGM-2; Lonza) and differentiated into myofibroblast  
49 by incubation with 5 ng/ml TGF-β1 (from a stock of 20 µg/ml in 4 mM HCl, 1 mg/ml BSA) for  
50 48 h. The final DMSO concentration in the assay was 0.6 % in all wells. 96 hours after seeding  
51 the medium was removed, and the cells were fixed in methanol for 10 min at room temperature  
52 (RT). After fixation, cells were washed three times with 1 x PBS and either stored at 4 °C for  
53 up to 3 days or further processed. The fixed cells were blocked with 10 % goat serum in 1 x  
54 PBS, 0.25 % Tween-20 for 60 min at RT. The primary antibody, i.e., mouse monoclonal anti-  
55 α-SMA (Sigma-Aldrich; A2547), was diluted 1:400 in 10 % goat serum (Invitrogen) in 1 x  
56 PBS, 0.25 % Tween-20 and the fixed cells were incubated with the antibody for 60 min at RT.  
57 After washing the cells three times with 1 x PBS, 0.25 % Tween-20 the detection antibody,  
58 i.e., goat anti-mouse AlexaFluor 488 (Invitrogen; A11029), was diluted 1:1000 in 1 x PBS,  
59 0.25 % Tween-20 and incubated for 1h at RT together with 1 µg/ml DAPI to stain the nuclei.  
60 The stained cells were washed three times with 1 x PBS containing 0.25 % Tween-20,  
61 followed by three washes in 1 x PBS, sealed with backing tape and stored at 4 °C. Images

62 were acquired on the Opera Phenix™ confocal high-content screening system (HCS, Perkin  
63 Elmer) using the 20-x water immersion lens.

64 *Image analysis:* The image data acquired with the HCS system were uploaded to ORBIT.  
65 ORBIT consists of several parts; one part is an open-source image analysis software  
66 developed at Idorsia Pharmaceuticals Ltd ([www.orbit.bio](http://www.orbit.bio)). The images were analyzed in a  
67 highly distributed way using AWS Batch by applying a CellProfiler pipeline. DAPI stained  
68 nuclei were used to identify cells.  $\alpha$ -SMA regions were then identified and mapped to the  
69 corresponding nuclei. After cell segmentation over 400 features, based on the stained cells,  
70 were calculated for each cell by CellProfiler as described (1). The computed features comprise  
71 granularity, intensity, texture, area, and shape of a cell in  $\alpha$ -SMA-expressing regions. NHLF  
72 grown as monocultures in dedicated wells on each assay plate were used to define 0% effect  
73 controls, i.e. undifferentiated FB. TGF- $\beta$ 1-mediated fully differentiated myofibroblast were  
74 used to define 100% effect controls. These controls were used to train and validate a support  
75 vector machine (SVM), a supervised learning model, which was then used to classify every  
76 NHLF as either FB or myofibroblast phenotype. The classification of each cell was aggregated  
77 to a cell type ratio per well, represented as the computed percentage effect value per well  
78 indicative of the degree of myofibroblast differentiation. The pipeline to process the images is  
79 available as Supplemental File 1.

#### 80 *Co-culture and protein quantification assay*

81 The following reagents were used for the RapidFire™ MS/MS experiments: 96-well flat bottom  
82 culture plate (Corning), 96-deep well plate and 96-well skirted polypropylene polymerase  
83 chain reaction (PCR) plate (Greiner), Oasis HLB-well plate 30  $\mu$ m (5 mg sorbent/well, Oasis),  
84 Dulbecco's phosphate-buffered saline (D-PBS, lacking  $\text{Ca}^{2+}/\text{Mg}^{2+}$ ), 10 x solution of HEPES  
85 and trypsin/EDTA (Invitrogen), tris hydrochloride (Tris-HCl, Applichem), benzonase nuclease  
86 (Sigma Aldrich), Tris (2-carboxyethyl) phosphine hydrochloride (TCEP, Sigma Aldrich),  
87 iodoacetamide (Sigma Aldrich), LC/MS grade formic acid 50 % (Sigma Aldrich), methanol and  
88 acetonitrile CHROMASOLV Plus for HPLC (Sigma Aldrich), urea BioXtra (Sigma Aldrich), as

89 well as thiourea ACS reagent (Sigma Aldrich). Complete™ Mini EDTA-free protease inhibitor  
90 tablets (Roche), ammonium bicarbonate (Fluka), sequencing grade modified trypsin. HPLC  
91 plus water (Sigma Aldrich).

92 *NHLF/NHBE co-culture:* NHLF were resuspended in FGM-2 growth medium (Lonza), mixed  
93 with an equal volume of NHBE in BEGM growth medium (Lonza), and seeded into a 96-well  
94 flat-bottom culture plate (Corning) at a density of 20000 and 1600 cells per well, respectively.  
95 Compound dilution series were added, and the co-culture was incubated for 18h at 37°C/5 %  
96 CO<sub>2</sub>. The medium was then replaced with FBM (Lonza) containing 0.1 % fatty acid-free BSA  
97 and the compounds at the indicated concentrations. The medium was supplemented with 100  
98 units/ml penicillin, 100 µg/ml streptomycin for the entire duration of the culture. If not indicated  
99 otherwise the co-culture was incubated at 37°C/5 % CO<sub>2</sub> for total 96 h.

100 *Lysis of cells for MS/MS analysis:* The cell culture medium was removed, and cells were lysed  
101 on ice by adding 5 µl/well of pre-cooled protein extraction buffer containing 10 mM Tris-HCl  
102 (pH 8.0), 6 M urea and 2 M thiourea and shaking on ice on a plate shaker at 600 rpm for 30  
103 min. Samples were prepared for MS/MS and surrogate tryptic peptides were chosen for  
104 detection of COL1 (COL1A1), α-SMA (ACTA2) and tubulin (TBA1A1) as described (1). Peak  
105 areas for COL1A1 and ACTA2 were normalized by dividing by TBA1A1 peak area.

#### 106 *Cell sampling by flow cytometry*

107 For each condition, 5 million NHLF cells were pre-stained with CellTrace™ Far Red  
108 (Invitrogen,) and the 1 million NHBE cells with CellTrace™ Violet (Invitrogen) according to the  
109 manufacturer's instructions, seeded, either separately or in combination, in full growth  
110 medium, at t = 0h and switched to starvation medium at t = 18h, then, at the indicated times  
111 after seeding, washed with 1x PBS, trypsinized and resuspended in autoMACS Rinsing  
112 Solution (Milteny Biotec) amended with 0.5% fatty acid-free BSA, forced through a 35 µm cell  
113 strainer (Corning) to achieve a single cell suspension, FACS sorted, using a cell sorter (SONY,  
114 SH800SE) with a 100 µm sorting chip (SONY, LE-C3100), followed by lysis in lysis buffer

115 (Norgen Biotek). Cells were sorted first based on forward – (FSC) and side scattering (SSC)  
116 thresholds, and then gated on CellTrace™ Far Red (638/660nm ex/em) and CellTrace™ Violet  
117 (405/421nm ex/em) staining intensities, respectively.

#### 118 *Gene expression analysis by qRT–PCR*

119 mRNA from NHLF, NHBE or FACS sorted co–cultured cells was isolated and reverse  
120 transcribed using the Cells–to CT protocol according to the manufacturers’ protocol (Thermo  
121 Fisher Scientific). QPCR was performed on a Biomark HD (Fluidigm) using 96\*96 dynamic  
122 arrays using TaqMan assays (Supplemental Table 10, Thermo Fisher Scientific). 18S was  
123 used as reference gene after selection from 7 reference candidates (18S, B2M, GUSB,  
124 HPRT1, PGK1, PPIA, YWHAZ) based on GENORM evaluation (2). Results were calculated  
125 using a modified delta delta cT method where an expression value of 1 reflects no detectable  
126 expression. This method allows a comparison between gene expression values for different  
127 genes, but also inter–cellular expression based on an identical linear scale. The data are  
128 shown as expression values for each gene in NHLF/NHBE from monoculture and NHLF/NHBE  
129 from co–culture which were FACS separated prior mRNA isolation.

#### 130 *Gene expression analysis by bulk RNAseq*

131 *Total RNA* extraction: Cells were isolated by FACS and lysed in RL Lysis Buffer from  
132 NORGEN Single cell RNA purification kit (Norgen). Total RNA was isolated using NORGEN  
133 Single cell RNA purification kit including a DNase treatment (Norgen), according to the  
134 manufacturer's instructions. Quality control was performed using Qubit 3.0 and RNA HS kit  
135 (Thermo Fisher Scientific). Quality was assessed with RNA PicoLabChip (Agilent) on a  
136 Bioanalyzer. In all samples the ratio of absorption at 260 nm/280 nm was between 1.8 and 2.2  
137 and the RNA Integrity Number (RIN) was > 8.00. All samples passed the quality thresholds.

138 *RNA–seq Library*: RNA–Seq libraries of poly(A)–selected RNA were isolated from 50 ng of  
139 total RNA using NuGen Universal Plus mRNA–Seq kit (NuGen) according to the  
140 manufacturer’s recommendations. Final library concentration was determined with Qubit HS

141 cDNA kit (Thermo Fisher Scientific) and quality was assessed with the Fragment Analyzer HS  
142 NGS kit (Agilent). Evaluation of the size, was performed based on a smear range of 100–1000  
143 bp with average size around 330 bp. In parallel qPCR quantification was performed using  
144 KAPA library quantification kit (Roche).

145 *RNA-seq* sequencing: For the sequencing runs the samples were randomized across two flow  
146 cells and sequenced using NextSeq 500/550high Output Kit v2.5 with 75 Cycles (Illumina).

147 *RNA-seq data processing*: Sequenced reads were aligned with STAR (v2.5.4b) to the human  
148 reference genome (GRCh38) and gene-wise alignments were quantified with featureCounts  
149 using *Ensembl* gene annotations. All samples passed quality control (QC) with more than 20  
150 million reads and over 90 % mapping rates. Good on-target (within annotated exons) mapping  
151 rates were observed for all samples (more than 80 %). Genes expressing less than 0.58 CPM  
152 (corresponding to a minimum of 10 reads) in less than 3 samples (smallest group size) were  
153 filtered, leaving 18380 genes in the final count table. Differentially expressed genes were  
154 evaluated in R (v4.0) using edgeR (3, 4) for each cell type and condition across time (i.e.  
155 NHLF, NHLF-CC, NHBE, NHBE-CC), where genes with an FDR < 0.05 and a linear fold  
156 change (linFC) > 1.5 were considered significant. Expression levels per gene were calculated  
157 as transcripts per million (TPM), defined as the number of aligned reads divided by gene length  
158 followed by normalization with library size (i.e. total number of on-target reads per sample  
159 divided by 1e6). Low expressed genes were filtered from the final DEG list, such that genes  
160 with an expression (TPM) below 1 across all samples were excluded from subsequent analysis  
161 (e.g. clustering).

162 *Gene expression signatures and their transcriptional regulation*: Lists of differentially  
163 expressed genes (DEG) among cell types were compared using Venn diagrams to distinguish  
164 specifically or commonly regulated genes. The resulting gene signatures were uploaded into  
165 Ingenuity Pathway Analysis (IPA, Ingenuity System, Qiagen) application for further biological  
166 interpretation.

167 *Upstream Regulator Analysis*, as implemented in the IPA software (Ingenuity System, Qiagen)  
168 and based on expected causal effects between upstream regulators and targets, was used to  
169 identify upstream regulators (separated by a “single hop”), that may be responsible for gene  
170 expression changes observed in the experimental dataset. IPA predicts which upstream  
171 regulators are activated or inhibited to explain the up-regulated and down-regulated genes  
172 observed in the dataset. An absolute z-score of  $\geq 2$  is considered significant. Predictions  
173 where both the z-score (absolute value  $> 2$ ) and the p-value (Fischer’s exact test) was  
174 significant ( $< 0.001$ ) were considered reliable predictions.

175 *Time series clustering*: Significantly expressed genes within each cell type (NHFL: 4877;  
176 NHLF-CC: 6289; NHBE: 6090; NHBE-CC: 6205) were clustered across time using a noise-  
177 robust soft clustering method based on the fuzzy c-means algorithm implemented in the R-  
178 package Mfuzz (5, 6). Gene expression values were converted to z-scores prior to clustering  
179 (for each gene, subtracted mean and divided by SD) using the function `standardize()` in the  
180 Mfuzz package. The number of time series clusters per cell type were evaluated by  
181 hierarchical clustering on the Euclidean distance between sample expression z-score vectors  
182 using Ward agglomeration method. Overlap between time series clusters of the different cell  
183 populations were illustrated using the R package UpSetR (7), an extension of Venn diagrams  
184 for visualization of overlapping sets.

185 *Gene Set Overexpression Analysis (GSOA)*: For each cell type, GSOA was performed for  
186 each time series cluster using the R package `hyperR` (8) with MSigDB (9, 10) and Enrichr (11,  
187 12) gene sets.

#### 188 *Single cell library preparation and sequencing*

189 NHLF and NHBE were combined at a ratio of 5 : 0.4 in full growth medium (FGM-2 and BEGM  
190 (1:1 vol./vol.; Lonza). After 18h medium was exchanged for FBM starvation medium (Lonza).  
191 The medium was supplemented with 100 units/ml penicillin, 100  $\mu\text{g}/\text{ml}$  streptomycin for the  
192 entire duration of the culture. The co-culture was then incubated at 37°C/5% CO<sub>2</sub>. After 3h,

193 and 50h, respectively, growth medium was aspirated and co-cultured cells in monolayer were  
194 gently detached using 0.05% trypsin/EDTA. Cells were resuspended in ice-cold FACS buffer  
195 (autoMACS Rinsing Solution, Miltenyi Biotec) supplemented with 0.5% fatty acid-free BSA  
196 (Calbiochem) to approximately  $1 \times 10^6$  cells/ml. Time point 0h cells were combined directly in  
197 ice-cold FACS buffer. Viability was determined using Trypan blue staining on an automatic  
198 Vi-Cell Analyzer. Average viability of all samples taken into single cell sequencing was 92.5%  
199 (88.4% – 94.8%). Cell suspensions were immediately loaded on a Chromium Next GEM Chip  
200 K (10X Genomics) targeting 10000 cells per channel for recovery. Single cell encapsulation  
201 and RNA capture was controlled on the Chromium Single Cell Controller. Single cell libraries  
202 were prepared using the Chromium Next GEM Single Cell 5' Kit v.2 reagents according to the  
203 manufacturer's recommendations. Final libraries were pooled and sequenced to an average  
204 depth of >42000 reads per cell on an Illumina NovaSeq system by Genewiz (Germany).

#### 205 *Single cell RNA-seq preprocessing*

206 Gene by cell counts matrices were processed from raw fastq files using Cellranger count  
207 (v4.0.0) by mapping against the human GRCh38 reference. The filtered gene matrices were  
208 loaded and further processed using Seurat v3.9.9.9002. As part of our stringent quality  
209 filtering, cell doublets were identified using scDbIFinder(13) (scDbIFinder: R package version  
210 1.4.0, <https://github.com/plger/scDbIFinder>) and removed. Additionally, we removed cells with  
211 > 15% mitochondrial reads or with > 60% ribosomal protein-coding gene reads. Low  
212 complexity cells with a log (genes per UMI) ratio of less than 0.8 were discarded. We further  
213 defined inclusion thresholds based on RNA molecule counts and detected genes count.

214 In brief, we used SCTransform (14) implemented in Seurat to perform per-sample  
215 normalization. As we noticed a pronounced effect of cell cycle phase in the first dimensions of  
216 a principal component analysis (PCA), we further regressed out cell cycle effects based on  
217 G2/M- and S-phase scores calculated in Seurat from a set of known cell cycle phase marker  
218 genes as described in Tirosh et al. (15). Normalized datasets were integrated using Seurat's  
219 anchor-finding workflow based on canonical correlation analysis (16). A first-level graph-

220 based clustering was performed on the full integrated dataset using the first 30 PCA  
221 dimensions for neighbor-finding and subsequent Louvain clustering using a resolution of 0.2.  
222 Choice of the resolution parameter was guided by assessing cluster partitioning using the  
223 clustree package (17). For visualization, UMAP embeddings were calculated based on the  
224 first 30 PCA dimensions. EC populations were determined based on known marker gene  
225 expression (*CDH1*, *EPCAM*, *TP63*) and used for sub-clustering analogous to the above  
226 workflow, using the first nine PCA dimensions and a resolution parameter of 0.25. Sub-cluster  
227 groups were reverse-annotated to refine the epithelial first-level clusters and projected into  
228 the same UMAP coordinates for visual consistency.

229 For labeling of clusters, we used a Wilcoxon rank sum test implemented in Seurat's  
230 FindConservedMarkers function to determine cluster-specific marker genes independent of  
231 timepoint or treatment. Test requirement was set to a minimum log-fold change of 0.25 and  
232 detection in at least 20 % of cells in a given cluster from up to 500 cells per cluster. Expression  
233 testing was performed on the log-normalized counts. Gene pathway assessment of markers  
234 with a Bonferroni-adjusted p value of less than 0.01 was performed using GSEA  
235 (<http://www.gsea-msigdb.org>).

### 236 *Single cell RNA-seq analysis*

237 *Differential state analysis:* A random forest classifier to predict culture time effect for each cell  
238 cluster group was built and tested using Augur (18) and default settings providing log-  
239 normalized RNA assay as input. Only clusters with a minimum of 20 cells were tested.

240 Pair-wise differential expression across timepoints or treatments was performed using MAST  
241 (19) implemented in Seurat after merging all EC into one group. Differential testing was  
242 performed for clusters with at least 40 cells total and a minimum of 10 cells per condition. Only  
243 genes detected in at least 15 % of cells in a cluster group and a minimum log-fold change of  
244 0.25 were tested. Expression testing was performed on the log-normalized counts. Results  
245 were filtered based on a Bonferroni-adjusted p-value of less than 0.1.

246 *Pseudotime*: Trajectory analysis was performed on the clustered vehicle group samples using  
247 the R package slingshot (v1.8.0)(20) on dimensionality reduced expression values (UMAP).  
248 The analysis was performed separately on EC and FB, using EC\_FBXO2 and FB\_APOE  
249 respectively as seed clusters. In addition, the Monocle3 (1.0.0)(21) R package was used to  
250 generate a more refined trajectory between cell states.

251 *Pathway enrichment analysis*: GSOA on DEGs was performed using the R package hyper  
252 (8) querying the MSigDB (9, 10) conserved pathways (CP) collection including the  
253 REACTOME – and BIOCARTA collection, the gene ontology (GO) collection with biological  
254 process (BP) –, cellular component (CC) –, and molecular function (MF) collection, as well as  
255 the Hallmark (H) collection gene sets, respectively. Gene sets with a FDR < 0.05 were deemed  
256 significant.

257 *Cell–Cell Interactions*: CellphoneDB (3.0.0)(22) was used to analyze cell–cell interactions. The  
258 analysis was performed separately on each sample (time point and condition). From the  
259 resulting interactions, the ligand receptor pairs were extracted omitting integrins and filtered  
260 such that only unique epithelial–FB interactions were retained. These interactions were  
261 visualized using Cytoscape(23).

#### 262 *Comparison with a human lung cell data set*

263 Curated data of control and fibrotic lung cells as published by Habermann et al (24) was  
264 downloaded (GSE135893). A subset of the data was generated to include relevant cell types  
265 (mesenchymal and EC from IPF patient or control donor (smoker reject lungs). This  
266 “reference” set of cells was re–processed via the default SCTransform workflow in parallel to  
267 the subset of vehicle–only cells from the co–culture assay (“query”). For each, reference and  
268 query, we determined the 8000 most variable genes and determined the union of overlapping  
269 variable genes that were mutually expressed in the reference and query data. Average per–  
270 cell log expression was calculated for each cluster and used to determine the reported  
271 Pearson correlations.

272 For the implementation of SingleR (25), we first trained a prediction model from the reference  
273 data counts, using all genes mutually detected in the reference and query subsets. For each  
274 reference cluster, we computed the top-100 positive marker genes using a Wilcoxon rank  
275 sum test. The query cells were individually profiled against this reference model using SingleR  
276 default settings. The reported prediction score corresponds to the 0.8 quantile of Spearman  
277 correlations for each cell across all reference cell types. The per-cell gene module co-  
278 expression scores were calculated using Seurat's "AddModuleScore" function using an  
279 approach implemented in (26). The score represents the average expression of the n module  
280 genes, subtracted by a control score for n \* 100 randomly selected genes with comparable  
281 expression.

#### 282 *RNAscope in situ hybridization*

283 Formalin-fixed, paraffin-embedded sections of human lungs with IPF or controls (obtained  
284 from areas distal to lung cancer resection) were obtained from extra material from subjects  
285 undergoing surgical lung biopsy for their respective condition at the University of Michigan.  
286 Samples were de-identified prior to receipt and thus did not require patient consent to obtain.  
287 RNAscope and immunofluorescence staining were performed as described (27, 28) using the  
288 following probes: Homo sapiens collagen type 1 alpha 1 (*COL1A1*) mRNA (Cat. No. 401898),  
289 Homo sapiens integrin subunit alpha V (*ITGAV*) transcript variant 1 mRNA (Cat. No. 488398),  
290 Homo sapiens integrin subunit beta 6 (*ITGB6*) mRNA (Cat. No. 312498). A digital  
291 quantification of the mRNA staining was performed using Orbit Image Analysis software,  
292 version 3.71(29). The nuclei and the mRNA signal areas were annotated manually.  
293 Supervised segmentation models of the annotated image structures were created and used  
294 to train a support vector machine classification model. Using a custom script in Orbit, the  
295 images were divided into 13.9µm x 13.9µm (64 x 64 pixels) regions. For each region, the ratio  
296 between the area of mRNA expression (red dots) and the area of the nuclei was formed and  
297 binned into 256 categories representing the signal intensity levels from 0 (no expression) to  
298 255 (very strong expression). To study the co-localization of the mRNA staining across


299 different tissue sections, the images were registered using the elastix framework  
300 [<https://www.bibsonomy.org/bibtexkey/journals%2ftmi%2fKleinSMVP10/dblp>]. The slide  
301 images showing the *COL1A1* expression were used as still reference images and the ones  
302 showing the expression of *ITGAV*, and *ITGB6*, were warped to align with the reference. B-  
303 spline transformations were computed to align with local changes. To provide an insightful  
304 rendering of the quantifications, the calculated signal intensities were further divided into  
305 coarser regions. In the case of the *COL1A1* gene expression the averaged signal intensity  
306 within 8 x 8 of the regions was rendered, while the maximum signal intensity of the *ITGAV* and  
307 *ITGB6* expression was rendered.

### 308 *Cell viability and cytotoxicity assay*

309 CHO-K1 cells (ATCC, CCL-61) were seeded, at a density of 20000 cells per well in a tissue  
310 culture-treated 96-well flat bottom culture plate (Costar) in Ham's F-12 (Gibco) supplemented  
311 with 10% non-heat-inactivated FBS (Amimed) and 1% Penicillin/Streptomycin (Gibco), with  
312 compounds at the indicated concentrations and incubated with the CellTox™ Green  
313 Cytotoxicity Assay (Promega) and RealTime-Glo™ MT Cell Viability Assay (Promega)  
314 reagents following the recommendations of the manufacturer. The fluorescence-associated  
315 membrane integrity (a surrogate for cytotoxicity) was calculated from the measured  
316 fluorescence (excitation/emission wavelength: 485 nm/530 nm), expressed as relative  
317 fluorescent units (RFU). The background fluorescence (cell-free wells; 0 % CellTox) was  
318 subtracted and the difference was expressed as a percentage in comparison to cells  
319 displaying maximum cytotoxicity (after addition of cell lysis buffer, 100 % CellTox). The  
320 luminescence-associated metabolic activity (a surrogate for cell viability) was calculated from  
321 the measured luminescence, expressed as relative luminescence units (RLU). The  
322 background signal (cell-free wells; 0 % viability) was subtracted and the difference was  
323 expressed as a percentage of the maximum metabolic activity (DMSO-treated cells, 100 %  
324 metabolic activity).

325


326 **Figures**



327


328 **Supplemental Figure 1. Expression of *COL1A1*, *ITGB6*, and *ITGAV* on computer-aligned**  
 329 **RNAscope-ISH overview images of lung sections.** Near consecutive tissue sections  
 330 showing the expression of epithelial marker genes integrin subunit beta 6 (*ITGB6*) and integrin  
 331 subunit alpha V (*ITGAV*), as well as the FB/myofibroblast marker collagen type 1 alpha 1  
 332 (*COL1A1*), as detected by RNAscope ISH on formalin-fixed, paraffin-embedded patient and  
 333 control lung sections. Images were computationally aligned using Q-path software. For the  
 334 analyzed genes, the RNAscope ISH signal was quantified for each grid square and projected  
 335 onto the tissue in false color as intensity. Across the entire lung section, *COL1A1*, *ITGB6*, and  
 336 *ITGAV* showed overlapping expression. Regions of high expression intensity exhibit a tissue-  
 337 specific intensity pattern and are more abundant in patients. For each gene, signal per square  
 338 area ( $1\mu\text{m}^2$ ) is quantified and expressed as false color intensity. Areas showing high  
 339 expression are shown as brighter signal intensity. *COL1A1* expression (red), representing the  
 340 FB/myofibroblast compartment, is shown aligned to the epithelial markers *ITGB6* and *ITGAV*  
 341 (green), respectively. All images were processed with the same settings.

342



343

344 **Supplemental Figure 2. Expression of *COL1A1*, *ITGB6* and *ITGAV* in control lungs. (A,**  
 345 **B)** Expression of *COL1A1*, *ITGB6* and *ITGAV*, as detected by RNAscope ISH on formalin–  
 346 fixed, paraffin–embedded control lung sections. Boxed area in the low magnification lung  
 347 section overviews in the left image indicates the enlarged region. The asterisks point to the  
 348 approximate same location in close consecutive tissue sections. **(A)** A representative section  
 349 of a denser tissue region and **(B)** a region with preserved alveolar tissue structure is shown.  
 350 **(C)** Histograms showing the distribution of RNA signal intensities of *COL1A1*, *ITGB6*, and  
 351 *ITGAV* in control and IPF patient lungs, as quantified by Orbit. Tissue sections were  
 352 segmented into areas of equal size, and the number of RNA signals per area was quantified  
 353 and divided by the nuclear area contained therein to normalize for cell number. Each area was  
 354 then categorized from 0 (no signal) to 255 (very strong signal intensity) and plotted, as a  
 355 histogram for each condition. X–axis: number of areas expressed on a log<sub>10</sub> scale; Y–axis:  
 356 graded signal intensity categories. The calculated area under the curve (AUC) represents a  
 357 measure for the total signal intensity per condition. *N* = 3 samples per condition.



358

359

360

361

362

363

364

365

366

367

368

369

370


371

372


373

**Supplemental Figure 3. EC in co-culture induce NHLF – and IHLF to myofibroblast differentiation.** High-content confocal microscopy images of **(A, B)** normal human lung fibroblasts (NHLF) and **(C)** IPF-patient-derived human lung fibroblasts (IHLF), which accumulate  $\alpha$ -SMA (green) to variable extent when co-cultured over a period of 5 days with primary normal human bronchial epithelial cells (NHBE; NHBEC), normal human tracheal epithelial cells (HTEC), immortalized epithelial cell lines (Calu-3; A427; A549; NCI-H2452; NCI-1975; NCI-1650), NHLF, IHLF, bronchial smooth muscle cells (BSMC), pulmonary artery smooth muscle cells (PASMC), or human umbilical vein endothelial cells (HUVEC). NHLF cells stimulated with TGF- $\beta$ 1 (5 ng/ml) served as positive control. 2'000 FB effector cells and 800 stimulating cells per well were seeded, respectively. Stimulating cells were stained with CellTracker Deep Red, nuclei with DAPI, and  $\alpha$ -SMA by using an anti- $\alpha$ -SMA antibody. The merged green and red channels are shown. **(D)** NHLF were titrated against NHBE to determine the effect of cell number and cell type ratio at seeding.


A



B




C




375

376 **Supplemental Figure 4. Conditioned co-culture supernatant is insufficient to trigger**  
 377 **pro-fibrotic changes in NHLF. (A)** Impedance recordings of NHLF cells. Cells were seeded  
 378 in full growth medium. After 18h medium was replaced by starvation medium supplemented  
 379 with conditioned cell culture supernatant in a 1:1 (vol/vol) ratio.  $N = 8$  for each condition. **(B)**  
 380  $\alpha$ -SMA and **(C)** COL1, normalized to tubulin, were quantified by MS/MS from NHLF cultured  
 381 with added supernatant of NHLF treated with 0.1% DMSO (SN NHLF vehicle), NHLF treated  
 382 with 5 ng/ml TGF- $\beta$ 1 in 0.1% DMSO (SN NHLF TGF- $\beta$ 1), NHBE treated with 0.1% DMSO  
 383 (SN NHBE vehicle), and NHLF/NHBE co-culture treated with 0.1% DMSO (SN co-culture  
 384 vehicle) for 80h, respectively. Bars depict mean  $\pm$  SD. A one-way ANOVA with Dunnett's  
 385 multiple comparison test was used.  $N = 16$  for each condition.

386



**Supplemental Figure 5. Capturing of cells for the analysis of early gene expression changes.** For each condition, NHLF cells were pre-stained with CellTrace Far Red and the NHBE cells with CellTrace Violet, seeded, either separately or in combination as depicted, at t = 0h and then FACS sorted, followed by lysis at t = 0h, 3h, and 18h. Left hand charts show scatter plots based on forward (FSC) and side scattering (SSC) profiles of monocultured (NHLF, NHBE) and of co-cultured (NHBE-CC, NHLF-CC) cells, as determined by flow cytometric analysis. Red line indicates gating threshold. Right hand panels: Gated cells were sorted on CellTrace Far Red and CellTrace Violet staining intensities, respectively. Blue and yellow gates indicate relative number of sorted NHLF and NHBE, expressed in (%) of total sorted cells, respectively.




**Supplemental Figure 6. Gene Set Overexpression Analysis in clusters of co-regulated genes in co-cultures of NHLF and NHBE. 6289 NHLF-CC genes and 6205 NHBE-CC**


404 genes showed a significant ( $FDR < 0.05$  and  $|\text{LinFC}| > 1.5$ ) change in gene expression from  $t = 0\text{h}$  with detected expression  $\text{max}(\text{count}) [\text{TPM}] > 1$ . Based on their gene expression changes  
405 over time NHLF-CC and NHBE-CC DEG were each assigned to 7 clusters of comparable  
406 size and as determined by the Mfuzz algorithm. **(A-G)** Expression kinetics and results of the  
407 gene set overexpression analysis (GSOA) of the seven NHLF-CC clusters and **(H-N)** of the  
408 seven NHBE-CC clusters. The comprised expression kinetics of the clustered genes is  
409 depicted as a z-score (from  $-1$  to  $1$ ; y-axis) across the time points  $t = 0\text{h}$ ,  $3\text{h}$ , and  $18\text{h}$ ,  
410 respectively (x-axis). The expression pattern of each gene is associated with a cluster weight  
411 between  $0$  and  $1$  (according to its match with cluster dynamics), color coded in the figure  
412 according to the inserted palette. For each cell type, GSOA was performed for each time series  
413 cluster using the R package hypeR querying the MSigDB Hallmark (H) and the JASPAR and  
414 TRRUST collections with gene sets provided by Enrichr. Enriched gene sets are displayed as  
415 bars representing the  $-\log_{10}(\text{FDR})$  with the corresponding FDR values.

417

A




B



419

420 **Supplemental Figure 7. Gene expression of NF- $\kappa$ B and AP-1 transcription factor**  
 421 **subunits in monocultured and co-cultured NHBE.** Gene expression, depicted in reads per  
 422 kilobase of transcript, per million mapped reads (RPKM), of (A) NF- $\kappa$ B and (B) AP-1  
 423 transcription factor family subunits for the conditions NHBE and NHBE-CC showing gene  
 424 expression differences between time points t=0h and 3h, or 18h, respectively. Differentially  
 425 expressed genes in comparison to monocultured control were evaluated using edgeR and are  
 426 depicted as \* FDR  $\leq$  0.05, \*\* FDR  $\leq$  0.01, \*\*\* FDR  $\leq$  0.001, and \*\*\*\* FDR  $\leq$  0.0001.

427




429

430 **Supplemental Figure 8. Cell viability and cytotoxicity of compounds.** Multiplexed viability  
 431 measurement depicting metabolic activity (RealTime–Glo™ MT) and cytotoxicity / membrane  
 432 integrity (CellTox™ Green). The compounds **(A)** EW–7197, **(B)** pirfenidone, **(C)** nintedanib,  
 433 **(D)** BAY 11–7082, **(E)** T–5224, **(F)** LLL12, and **(G)** stattic were added to the CHO–K1 cells at  
 434  $t = 0\text{h}$  covering the concentration range 0.025 nM – 25000 nM, except for pirfenidone which  
 435 was tested at 0.01  $\mu\text{M}$  – 10000  $\mu\text{M}$  and incubated with the CellTox™ Green – and RealTime–  
 436 Glo™ MT reagents for 18h. The fluorescence–associated cytotoxicity and the luminescence–  
 437 associated metabolic activity (a surrogate for cell viability) was calculated as described in the  
 438 Material and Method section and expressed as a percentage of the maximum cytotoxicity  
 439 (addition of cell lysis buffer; 100% cell tox) or metabolic activity (DMSO–treated cells, 100%  
 440 metabolic activity), respectively. 0.25 % DMSO solvent was present in all wells.  $N = 2$ .


441

442


**A**



**B**




**C**



443

444 **Supplemental Figure 9. The NF- $\kappa$ B inhibitor BAY 11-7082 blocks cytokine production**  
 445 **in the co-culture. (A)** Box and whisker plot expression, as depicted in reads per kilobase of  
 446 transcript, per million mapped reads (RPKM), in NHLF (F) and NHLF-CC (F-CC), of *IL6*,  
 447 *CXCL8/IL8*, *CXCL6*, and *TNF* at t = 0h (T0), 3h (T3), and 18h (T18), respectively. **(B)** Effect  
 448 of the NF- $\kappa$ B inhibitor BAY 11-7082, and **(C)** c-FOS/AP-1 inhibitor T-5224 incubated with  
 449 the co-cultured NHBE-CC and NHLF-CC from t = 0h until t = 18h, at the indicated  
 450 concentrations, on levels of secreted IL-6, IL-8 and CXCL6 at t = 98h, as determined by  
 451 Luminex and depicted in (pg/ml).

452




453

454

455 **Supplemental Figure 10. Effect of c-FOS/AP-1, and IKK/NF-κB inhibition on marker**  
 456 **gene expression at sub-population resolution. (A)** UMAP embeddings of jointly analyzed  
 457 single cell transcriptomes from 18,676 vehicle control cells collected at the time points t = 0h,  
 458 3h, and 50h, respectively, overlaid with the expression (log normalized counts) of *ACTA2*,  
 459 *CCN2*, or *IL6* are shown next to violin plots depicting the expression *ACTA2*, *CCN2*, and *IL6*,  
 460 separated by sample, for the cell sub-state “FB COL1A1”. **(B)** Venn diagram representation  
 461 of epithelial cell genes affected by each treatment at t = 50h. **(C)** Violin plots depicting the  
 462 expression, separated by sample, of marker genes *KRT5*, *KRT6A*, *KRT8*, *KRT14*, *KRT17*,  
 463 *KRT18*, *KRT19*, *TP63*, *GPR87*, *PDPN*, *SOX9*, *SOX4*, *HES1*, and *HES4* at the level of sub-  
 464 clustered cell state identifier “EC KRT18”. Cells were either untreated (vehicle) or treated (i.e.  
 465 2.5 μM BAY 11-7082, 25 μM T-5224) and collected at the time points t = 0h, 3h, or 50h,  
 466 respectively. Normalized gene expression is depicted as log(counts+1) for a non-statistical  
 467 overview of gene-of-interest expression in the dataset.

468




469

470

471 **Supplemental Figure 11. Enriched canonical pathways and function in the EC at t = 3h.**  
 472 Effect of the NF- $\kappa$ B inhibitor BAY 11-7082 (2.5  $\mu$ M) or vehicle control, applied from t = 0h, on  
 473 overrepresented gene sets in the EC DEG, identified by MAST, at time t = 3h vs t = 0h,  
 474 displayed as bars representing the  $-\log_{10}(\text{FDR})$  of the MSigDB data base query results using  
 475 hypeR. **(A)** conserved pathways (CP); REACTOME -, **(B)** gene ontology (GO); biological  
 476 processes (BP) -, **(C)** GO; cellular components (CC) -, **(D)** CP; Kyoto Encyclopedia of Genes  
 477 and Genomes (KEGG) -, **(E)** GO; molecular function (MF) -, and **(F)** Hallmark gene sets.

478



479

480 **Supplemental Figure 12. Expression of AP-1 and NF-κB gene modules in cell**  
 481 **populations isolated from IPF patient lungs.** Results of the module score analysis querying  
 482 the Habermann reference human IPF patient lung cell atlas (24) with the gene expression  
 483 modules (A) AP-1, (B) NF-κB, and (C) “TNF-α Signaling via NF-κB”. The UMAP space of  
 484 control and interstitial lung disease (ILD) cells is overlaid with the obtained module scores for  
 485 each individual cell. Box plots display module scores (x-axis) obtained for the respective  
 486 reference cell populations (y-axis) in control (red boxes) and ILD patient-derived (turquoise  
 487 boxes) cells.

488

489

490 **Tables**491 **Supplemental Table 1. DEG list mono vs co-culture at t = 3h and t = 18h.**492 **Supplemental Table 2. Co-culture specific genes associated with top-ranked canonical**  
493 **pathways**494 **Supplemental Table 3. IPA predicted Upstream Regulators of 1599 NHLF-CC DEG (t =**  
495 **3h)**

Upstream Regulator	Molecule Type	Predicted Activation State	Activation z-score	* p-value
TNF	cytokine	Activated	7.891	1.16E-21
IL1A	cytokine	Activated	5.23	2.51E-16
NFkB (complex)	complex	Activated	7.829	2.86E-15
IL1B	cytokine	Activated	6.884	1.31E-13
CSF2	cytokine	Activated	2.485	1.52E-12
IFNG	cytokine	Activated	4.412	1.16E-11
CHUK	kinase	Activated	5.482	1.43E-11
TP53	transcription regulator	Activated	2.664	2.32E-11
ERK	group	Activated	4.198	3.86E-11
IKKBK	kinase	Activated	5.446	7.72E-11
poly rI:rC-RNA	biologic drug	Activated	5.045	1.75E-10
NOD2	other	Activated	3.449	3.12E-10
ECSIT	transcription regulator	Activated	3.501	1.5E-09
NFKBIA	transcription regulator	Activated	2.792	2.31E-09
CD40LG	cytokine	Activated	3.666	2.34E-09
CDKN1A	kinase	Activated	2.359	2.56E-09
STAT3	transcription regulator	Activated	3.845	3.25E-09
IKBKG	kinase	Activated	4.028	4.39E-09
RELA	transcription regulator	Activated	5.309	4.52E-09
RABL6	other	Inhibited	-2.982	6.87E-09
IL4	cytokine	Activated	2.84	6.93E-09
TNFSF11	cytokine	Activated	4.017	2.33E-08
CD40	transmembrane receptor	Activated	4.916	2.78E-08

CDKN2A	transcription regulator	Activated	3.487	4.81E-08
--------	-------------------------	-----------	-------	----------

496 \* Top-ranked. Data were sorted according to the ascending p-value.

497

498 **Supplemental Table 4. IPA predicted Upstream Regulators of 1364 NHBE-CC DEG (t =**

499 **3h)**

Upstream Regulator	Molecule Type	Predicted Activation State	Activation z-score	*p-value
miR-369-5p	mature microRNA	Activated	2.111	1.58E-07
CDKN2A	transcription regulator	Activated	2.077	1.27E-05
TNF	cytokine	Activated	2.965	1.97E-05
CCND1	transcription regulator	Inhibited	-2.074	6.98E-05
NUPR1	transcription regulator	Activated	3.175	1.17E-04
RELA	transcription regulator	Activated	2.411	4.88E-04
PDLIM2	other	Inhibited	-2.138	5.24E-04
NFkB (complex)	complex	Activated	2.446	9.37E-04

500 \* Top-ranked; adjusted p-value < 0.001. Data were sorted according to the ascending p-value.

501

502 **Supplemental Table 5. IC<sub>50</sub> values for small molecule inhibitors**

Compound name	Activity	MS/MS α-SMA	MS/MS COL1
		IC <sub>50</sub> [nM]	IC <sub>50</sub> [nM]
EW-7197	ALK5 inhibitor	17 ± 13 (n = 8)	20 ± 7 (n = 8)
pirfenidone	n.a.	>1'0000'000 (n = 6)	6'577'000 ± 3'860'000 (n = 6)
nintedanib	EGFR/VEGFR/FGFR inhibitor	277 ± 287 (n = 4)	214 ± 70 (n = 6)
BAY 11-7082	IKK/NF-κB inhibitor	415 ± 403 (n = 4)	428 ± 241 (n = 4)
T-5224	c-FOS/AP-1 inhibitor	17930 ± 9366 (n = 4)	10267 ± 9557 (n = 4)
stattic	STAT3 inhibitor	52 ± 29 (n = 3)	446 ± 353 (n = 3)
LLL12	STAT3 inhibitor	22 ± 13 (n = 3)	80 ± 2 (n = 3)

503 Values represent mean ± SD; n, number of independent experiments. Abbreviations: n.a. not annotated; n.d. not determined.

504

505 **Supplemental Table 6. Variable gene expression Pearson correlations at cluster level**

506 **Supplemental Table 7. Variable gene expression Pearson correlations at sub-cluster**

507 **level**

508 **Supplemental Table 8. Fractional contribution of SingleR correlated co-culture cells to**

509 **query populations**

510 **Supplemental Table 9. Cell number at sub-cluster level**

511 **Supplemental Table 10. TaqMan Assays**

<b>Gene</b>	<b>Assay</b>
ACTA2	Hs00426835_g1
CCN2/CTGF	Hs00170014_m1
CDH1	Hs01023894_m1
COL1A1	Hs00164004_m1
CXCL6	Hs00605742_g1
CXCL8/IL8	Hs00174103_m1
EDN1	Hs00174961_m1
ELN	Hs00355783_m1
FN1	Hs00365052_m1
GPR87	Hs00225057_m1
IL6	Hs00985639_m1
ITGB6	Hs00168458_m1
KRT5	Hs00361185_m1
PDGFA	Hs00964426_m1
PDPN	Hs00366766_m1
TGFB1	Hs00171257_m1
TNF	Hs01113624_g1
TP63	Hs00978340_m1
VIM	Hs00185584_m1
<b>Reference genes</b>	<b>Assay</b>
18s	Hs99999901_s1

B2M	Hs00984230_m1
GUSB	Hs00939627_m1
HPRT1	Hs02800695_m1
PGK1	Hs00943178_g1
PPIA	Hs04194521_s1
YWHAZ	Hs03044281_g1

512

513 **Supplemental Table 11. Mapping of Habermann(24) cell identity labels to proposed**  
514 **consensus re-annotation of integrated single-cell transcriptomic human lung cell**  
515 **atlas(30)**

Cell identity labels as used by Habermann, Banovich, and Kropski et al. (24)	Proposed consensus hierarchical reference frame of the integrated single-cell transcriptomic atlas of the human lung(30)
Basal Epithelial Cells	Basal
KRT5-/KRT17+ Epithelial Cells	KRT5-/KRT17+ epithelial
PLIN2+ Fibroblasts	Fibroblasts PLIN2+
HAS1 High Fibroblasts	Subpleural fibroblasts
Myofibroblasts	Myofibroblasts
Smooth Muscle Cells	Smooth Muscle

516

517 **Supplemental Table 12. R functions with specified arguments**

## 518 **Files**

519 **Supplemental File 1. Cell Profiler Pipeline**

## 520 **References**

521 1. Sieber P, Schafer A, Lieberherr R, Le Goff F, Stritt M, Welford RWD, et al. Novel high-  
522 throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary  
523 fibrosis that act via EP2 and EP4 receptors. *PLoS One*. 2018;13(11):e0207872.

- 524 2. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate  
525 normalization of real-time quantitative RT-PCR data by geometric averaging of multiple  
526 internal control genes. *Genome Biol.* 2002;3(7):RESEARCH0034.
- 527 3. McCarthy DJ, Chen Y, and Smyth GK. Differential expression analysis of multifactor RNA-Seq  
528 experiments with respect to biological variation. *Nucleic Acids Res.* 2012;40(10):4288-97.
- 529 4. Robinson MD, McCarthy DJ, and Smyth GK. edgeR: a Bioconductor package for differential  
530 expression analysis of digital gene expression data. *Bioinformatics.* 2010;26(1):139-40.
- 531 5. Futschik ME, and Carlisle B. Noise-robust soft clustering of gene expression time-course data.  
532 *J Bioinform Comput Biol.* 2005;3(4):965-88.
- 533 6. Kumar L, and M EF. Mfuzz: a software package for soft clustering of microarray data.  
534 *Bioinformatics.* 2007;2(1):5-7.
- 535 7. Conway JR, Lex A, and Gehlenborg N. UpSetR: an R package for the visualization of intersecting  
536 sets and their properties. *Bioinformatics.* 2017;33(18):2938-40.
- 537 8. Federico A, and Monti S. hypeR: an R package for geneset enrichment workflows.  
538 *Bioinformatics.* 2020;36(4):1307-8.
- 539 9. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, and Mesirov JP.  
540 Molecular signatures database (MSigDB) 3.0. *Bioinformatics.* 2011;27(12):1739-40.
- 541 10. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set  
542 enrichment analysis: a knowledge-based approach for interpreting genome-wide expression  
543 profiles. *Proc Natl Acad Sci U S A.* 2005;102(43):15545-50.
- 544 11. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and  
545 collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics.* 2013;14:128.
- 546 12. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a  
547 comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.*  
548 2016;44(W1):W90-7.
- 549 13. Germain PL, Sonrel A, and Robinson MD. pipeComp, a general framework for the evaluation  
550 of computational pipelines, reveals performant single cell RNA-seq preprocessing tools.  
551 *Genome Biol.* 2020;21(1):227.
- 552 14. Hafemeister C, and Satija R. Normalization and variance stabilization of single-cell RNA-seq  
553 data using regularized negative binomial regression. *Genome Biol.* 2019;20(1):296.
- 554 15. Tirosh I, Izar B, Prakadan SM, Wadsworth MH, 2nd, Treacy D, Trombetta JJ, et al. Dissecting  
555 the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science.*  
556 2016;352(6282):189-96.
- 557 16. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, et al.  
558 Comprehensive Integration of Single-Cell Data. *Cell.* 2019;177(7):1888-902 e21.
- 559 17. Zappia L, and Oshlack A. Clustering trees: a visualization for evaluating clusterings at multiple  
560 resolutions. *Gigascience.* 2018;7(7).
- 561 18. Skinnider MA, Squair JW, Kathe C, Anderson MA, Gautier M, Matson KJE, et al. Cell type  
562 prioritization in single-cell data. *Nat Biotechnol.* 2021;39(1):30-4.
- 563 19. Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, et al. MAST: a flexible statistical  
564 framework for assessing transcriptional changes and characterizing heterogeneity in single-  
565 cell RNA sequencing data. *Genome Biol.* 2015;16:278.
- 566 20. Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, et al. Slingshot: cell lineage and  
567 pseudotime inference for single-cell transcriptomics. *BMC Genomics.* 2018;19(1):477.
- 568 21. Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, et al. Reversed graph embedding resolves  
569 complex single-cell trajectories. *Nat Methods.* 2017;14(10):979-82.
- 570 22. Efremova M, Vento-Tormo M, Teichmann SA, and Vento-Tormo R. CellPhoneDB: inferring cell-  
571 cell communication from combined expression of multi-subunit ligand-receptor complexes.  
572 *Nat Protoc.* 2020;15(4):1484-506.

- 573 23. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software  
574 environment for integrated models of biomolecular interaction networks. *Genome Res.*  
575 2003;13(11):2498-504.
- 576 24. Habermann AC, Gutierrez AJ, Bui LT, Yahn SL, Winters NI, Calvi CL, et al. Single-cell RNA  
577 sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in  
578 pulmonary fibrosis. *Sci Adv.* 2020;6(28):eaba1972.
- 579 25. Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-  
580 cell sequencing reveals a transitional profibrotic macrophage. *Nat Immunol.* 2019;20(2):163-  
581 72.
- 582 26. Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, et al. Single-cell RNA-seq  
583 supports a developmental hierarchy in human oligodendroglioma. *Nature.*  
584 2016;539(7628):309-13.
- 585 27. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA  
586 analysis platform for formalin-fixed, paraffin-embedded tissues. *J Mol Diagn.* 2012;14(1):22-  
587 9.
- 588 28. Wang H, Su N, Wang LC, Wu X, Bui S, Nielsen A, et al. Quantitative ultrasensitive bright-field  
589 RNA in situ hybridization with RNAscope. *Methods Mol Biol.* 2014;1211:201-12.
- 590 29. Stritt M, Stalder AK, and Vezzali E. Orbit Image Analysis: An open-source whole slide image  
591 analysis tool. *PLoS Comput Biol.* 2020;16(2):e1007313.
- 592 30. Sikkema L, Strobl D, Zappia L, Madissoon E, Markov N, Zaragosi L, et al. An integrated cell atlas  
593 of the human lung in health and disease. *bioRxiv.* 2022:2022.03.10.483747.

594

595